Brand-specific enhanced safety surveillance of GSK's Fluarix Tetra seasonal influenza vaccine in England: 2017/2018 season
Open Access
- 2 August 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Human Vaccines & Immunotherapeutics
- Vol. 16 (8), 1762-1771
- https://doi.org/10.1080/21645515.2019.1705112
Abstract
In compliance with the European Medicine Agency guidance to detect any potential safety concerns associated with influenza vaccination, an enhanced safety surveillance study was conducted in England during the 2017/18 influenza season. The primary objective was to estimate the incidence rates of adverse events occurring within seven days of vaccination with Fluarix Tetra. In nine General Practices, seasonal influenza vaccine was administered to patients according to local guidelines. Events following immunization were collected using customized cards (enhanced component) combined with electronic health records [EHRs] (EHR component) to estimate incidence rates of adverse events experienced post vaccination. The study ran from 01-Sep-2017 to 30-Nov-2017. A total of 23,939 subjects were vaccinated of whom 16,433 received Fluarix Tetra. The cumulative incidence rates of adverse events of interest for Fluarix Tetra were 7.25% [95% CI, 5.95-8.73] for events reported by card alone, and 9.21% [95% CI, 7.37-11.34] when combined with EHR data. The type and frequency of events reported were consistent with the Fluarix Tetra Summary of Product Characteristics. The study supports and confirms the safety profile of Fluarix Tetra. ClinicalTrials.gov number: NCT03278067Funding Information
- GlaxoSmithKline foundation (RH8028)
This publication has 13 references indexed in Scilit:
- Uptake and impact of vaccinating primary school-age children against influenza: experiences of a live attenuated influenza vaccine programme, England, 2015/16Eurosurveillance, 2018
- RCGP Research and Surveillance Centre: 50 years’ surveillance of influenza, infections, and respiratory conditionsBritish Journal of General Practice, 2017
- Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in EnglandBMJ Open, 2017
- Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16Eurosurveillance, 2017
- Influenza vaccination: in the UK and across EuropeBritish Journal of General Practice, 2016
- Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profileBMJ Open, 2016
- Planning for a cohort study to investigate the impact and management of influenza in pregnancy in a future pandemicHealth Services and Delivery Research, 2015
- Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant.Health Technology Assessment, 2010
- The Index of Multiple Deprivation 2000 and accessibility effects on healthJournal of Epidemiology and Community Health, 2004
- Adverse drug reactions in elderly patientsBritish Journal of Clinical Pharmacology, 2003